Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF

AIMS: Among patients with heart failure (HF) and reduced ejection fraction (HFrEF), those with atrial fibrillation (AF) may respond differently to certain treatments than patients without AF. We investigated the efficacy and safety of dapagliflozin in patients with HFrEF with and without AF in the D...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Jawad H., Docherty, Kieran F., Jhund, Pardeep S., de Boer, Rudolf A., Böhm, Michael, Desai, Akshay S., Howlett, Jonathan G., Inzucchi, Silvio E., Kosiborod, Mikhail N., Martinez, Felipe A., Nicolau, Jose C., Petrie, Mark C., Ponikowski, Piotr, Bengtsson, Olof, Langkilde, Anna Maria, Schou, Morten, Sjöstrand, Mikaela, Solomon, Scott D., Sabatine, Marc S., McMurray, John J.V., Køber, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Comorbidities
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234442/
https://www.ncbi.nlm.nih.gov/pubmed/34766424
http://dx.doi.org/10.1002/ejhf.2381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234442/
https://www.ncbi.nlm.nih.gov/pubmed/34766424
http://dx.doi.org/10.1002/ejhf.2381

Ejemplares similares